ENVALITH
株式会社クスリのアオキホールディングス logo

KUSURI NO AOKI HOLDINGS CO.,LTD.

3549Prime MarketRetail Trade

株式会社クスリのアオキホールディングス logo
KUSURI NO AOKI HOLDINGS CO.,LTD.3549

Business

Kusuri no Aoki Holdings Co., Ltd. is a holding company established in 1985 (its predecessor was a drug wholesaler founded in 1869) that operates a Neighborhood Retail Business (Single Segment) centered on drugstores handling pharmaceuticals, cosmetics, daily necessities, food, and dispensing pharmacy services. Its core subsidiary, Kusuri no Aoki Co., Ltd., holds the top market share across five prefectures in the Hokushinetsu region and is actively expanding its store network into the Tohoku, Kanto, Tokai, Kansai, and Shikoku areas. As of the end of FY2025 (ended May 2025), the company operated a total of 1,036 stores, consisting of 1,004 drugstores (of which 664 include an attached dispensing pharmacy), 6 dedicated dispensing pharmacies, and 26 supermarkets. Through strengthening its food division—including fresh food offerings—and acquiring and integrating supermarket operations via M&A, the company is accelerating its transition toward a one-stop food-and-drug shopping format. Its primary customers are local residents, and it has built a community-oriented business model that addresses everyday health, beauty, and dietary needs in a single location.

Business Model

The company stocks products across five divisions—Health, Beauty, Life, Food, and Pharmacy Dispensing—capturing local residents' daily needs through store formats ranging from 150 to 500 tsubo. The Food Division (51.3% of sales composition) is the largest revenue source, while the Pharmacy Dispensing Division (10.3%) provides stable earnings by capturing outpatient prescriptions. The business structure combines scale expansion through new store openings and M&A with existing store renovations (rolling out fresh food across all stores) to improve visit frequency and customer spend per transaction. Joint product development and joint procurement through business and capital alliances with Tsuruha and Aeon also support profitability.

Company Strengths

The company operates 388 stores across the five Hokushinetsu prefectures (Ishikawa, Toyama, Fukui, Niigata, and Nagano), establishing the top market share in the region. In FY2025 (ended May 2025), sales in the Hokushinetsu area reached ¥212,789 million (42.4% of total sales), and the region-focused dominant strategy has formed a stable customer base.

Of the 1,004 drugstores, 664 stores (66.1%) have an attached dispensing pharmacy, functioning as community-based primary pharmacies. In FY2025 (ended May 2025), sales in the Pharmacy Dispensing Division reached ¥51,885 million (up 12.4% year on year), reflecting stable growth driven by a continued increase in the number of outpatient prescriptions received.

During FY2025 (ended May 2025), the company acquired and integrated Kimuraya, Moomy, Happy Terada, Super Yoshimura, the Fushimiya Group, and others, newly adding 72 Supermarket Business stores. Sales grew 64% over four years, from ¥305,880 million in FY2021 (ended May 2021) to ¥501,470 million in FY2025 (ended May 2025).

ENVALITH's Perspective

In FY2026 (ending May 2026), net sales reached ¥566,865 million (up 13.0% year on year), maintaining high growth, while operating profit was only ¥27,096 million (up 1.9% year on year), and the operating margin declined from 5.3% to 4.8%. The expanding sales mix of the Food & fresh produce category is emerging as a structural challenge that is depressing the gross margin. External factors such as rising prices, escalating labor costs, and persistently high energy costs are also pushing up SG&A expenses, warranting close scrutiny of the path toward margin improvement.

In FY2026 (ending May 2026), the company acquired ¥23,869 million of treasury shares and cancelled 9,480,700 shares (¥34,066 million). Shareholder returns were significantly strengthened, with annual dividends of ¥56 per share (dividend payout ratio of 31.1%), including a commemorative dividend of ¥40 for the company's 40th anniversary. However, net assets declined from ¥145,759 million to ¥141,038 million, and the equity ratio fell from 41.4% to 34.3%. The concurrent execution of aggressive borrowing (long-term borrowings balance of ¥119,901 million) and treasury share acquisitions is increasing financial leverage, and the trend in financial soundness warrants close monitoring.

The company's forecast for FY2027 (ending May 2027) calls for net sales of ¥640,000 million (up 12.9% year on year) and operating profit of ¥32,000 million (up 18.1% year on year), anticipating substantial profit improvement. The company plans to open 90 new Drugstore (Health, Beauty, Life & Food Division) stores and 31 new Dispensing Pharmacy (Pharmacy Dispensing Division) locations. However, accelerating industry consolidation, intensifying store-opening competition among rivals, and difficulty securing qualified personnel such as pharmacists could become bottlenecks to achieving the plan. As an external factor, the continuation of consumers' preference for low prices may also affect the profitability of the Food division.

Growth Strategy

Expanding dominant areas nationwide through a three-pronged approach of new store openings, M&A, and food category enhancement

Opened 111 new stores in FY2026 (ending May 2026), building a network of 1,107 stores by fiscal year-end. For FY2027 (ending May 2027), the company plans to open 90 new drugstores, continuing to deepen its dominance in Hokushinetsu, Tohoku, Kanto, Tokai, Kansai, and Shikoku. The company will pursue economies of scale by accelerating store openings.

Promoting a "Food & Drug" one-stop shopping model through expansion of the food category, including fresh food. In FY2026 (ending May 2026), fresh food sales grew 21.4% year on year, and food (excluding fresh food) grew 16.0% year on year, both showing high growth. The company will continue to review product assortment at existing stores and increase the proportion of fresh food.

Opened 38 new pharmacies in FY2026 (ending May 2026), expanding the number of stores co-located with a Dispensing Pharmacy (Pharmacy Dispensing Division) to 692 stores (co-location rate of 62.5%). Pharmacy dispensing sales grew 15.3% year on year, showing high growth. For FY2027 (ending May 2027), the company plans to open 31 new pharmacies, strengthening its position as a community pharmacy of choice.

Acquired Miwa Shoten Co., Ltd. in Kagawa Prefecture in June 2025, and multiple food supermarket businesses in Niigata Prefecture in February 2026, newly acquiring 37 supermarket stores. The number of supermarket stores at fiscal year-end stood at 31 (of which 1 store is co-located with a dispensing pharmacy). The company aims to accelerate its Food & Drug strategy through synergies with food supermarkets.

Last updated: July 17, 2026